The Gallup National Health and Well-Being Index shows that GLP-1 weight loss drugs are having an effect: The U.S. obesity rate is at 37%, down from 39.9%.
Source: GLP-1 drugs are making a dent in the high obesity rate in the U.S. : Shots – Health News : NPR
fta:
The survey found that the number of Americans taking drugs like semaglutide (which include the brands Ozempic and Wegovy) or tirzepatide (under the brands Zepbound and Mounjaro) for weight loss more than doubled over the past year and a half. That’s 12.4% of respondents taking the drugs compared with 5.8% in February 2024, when Gallup first measured it. The new treatments are in a class of drugs known as GLP-1 agonists, and this generation of very effective GLP-1 agonists were approved for obesity treatment in the U.S. market in 2021.
